185 related articles for article (PubMed ID: 6378530)
1. Pharmacokinetics and toxicity testing.
Clark B; Smith DA
Crit Rev Toxicol; 1984; 12(4):343-85. PubMed ID: 6378530
[TBL] [Abstract][Full Text] [Related]
2. [Species differences in pharmaco-kinetics of chemicals. Correlations with toxicity (author's transl)].
Keck G
Toxicol Eur Res; 1981 Jul; 3(4):207-15. PubMed ID: 7302948
[TBL] [Abstract][Full Text] [Related]
3. An overview of the analysis and interpretation of bioavailability studies in man.
Wagner JG
Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic and metabolic studies in the development of drugs].
Vereczkey L
Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
[TBL] [Abstract][Full Text] [Related]
5. Primer on clinical pharmacokinetics.
Bauer LA
Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025
[TBL] [Abstract][Full Text] [Related]
6. Absorption, distribution, metabolism, and excretion of griseofulvin in man and animals.
Lin C; Symchowicz S
Drug Metab Rev; 1975; 4(1):75-95. PubMed ID: 1106976
[No Abstract] [Full Text] [Related]
7. [Age-related aspects of pharmacokinetics (a review of the literature)].
Bezverkhaia IS; Zapadniuk VI
Farmakol Toksikol; 1980; 43(1):115-9. PubMed ID: 6991280
[No Abstract] [Full Text] [Related]
8. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
9. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
Cabana BE
Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
[TBL] [Abstract][Full Text] [Related]
10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of residues: current status.
Huber WG; Becker SR; Archer BP
J Environ Pathol Toxicol; 1980; 3(5-6):45-63. PubMed ID: 7003045
[TBL] [Abstract][Full Text] [Related]
12. The concept of multispecies testing in industrial toxicology.
Zbinden G
Regul Toxicol Pharmacol; 1993 Feb; 17(1):85-94. PubMed ID: 8441831
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
14. Systemic availability and pharmacokinetics of some drugs in ruminant animals.
Baggot JD
Vet Hum Toxicol; 1987; 29 Suppl 1():84-8. PubMed ID: 3303648
[No Abstract] [Full Text] [Related]
15. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
16. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
[TBL] [Abstract][Full Text] [Related]
18. [The use of the concepts of "half-life" and "clearance" in practice and in pharmacokinetics].
Raaflaub J
Schweiz Med Wochenschr; 1981 Sep; 111(38):1406-11. PubMed ID: 7280641
[TBL] [Abstract][Full Text] [Related]
19. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
[TBL] [Abstract][Full Text] [Related]
20. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a).
Usansky HH; Sinko PJ
J Pharmacol Exp Ther; 2005 Jul; 314(1):391-9. PubMed ID: 15833900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
